Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that castration increased 5 alpha-reductase activity in the sebaceous glands of male hamsters, but administering testosterone propionate or 5 alpha-dihydrotestosterone inhibited this effect.

This study demonstrated that steroidal carbamates 7–10 altered mRNA expression related to lipid metabolism in hamster flank organs and inhibited 5α-reductase activity without binding to the progesterone receptor.

This study found that various steroids affected the mRNA expression of enzymes involved in lipid metabolism in hamster flank organs, with different impacts depending on the steroid and combination used.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

Finasteride affects prostate weights and pituitary activity differently with age.

This study found that several synthesized pregnane derivatives exhibited significant inhibitory effects on testosterone conversion to dihydrotestosterone and reduced related androgenic parameters in multiple pharmacological models.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

This article discusses whether testosterone's metabolism to 5α-dihydrotestosterone is necessary for androgenic effects in the skin but reports no new experimental results.

This study suggests that in rat skin, testosterone itself may play a more significant role in androgen action than 5α-dihydrotestosterone, unlike in the prostate where 5α-DHT is more dominant.

This study identified pantolactam based compounds as effective topical antagonists of the androgen receptor, reducing sebum components in a hamster model.

This study found that the phytosterols β-sitosterol, stigmasterol, and campesterol have low-to-negligible inhibitory activity against steroidal 5α-reductase type 2 compared to the synthetic inhibitor dutasteride, with β-sitosterol showing the highest activity among the tested phytosterols.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This review discusses the pharmacological properties and clinical applications of cyproterone acetate and similar antiandrogens, noting previous failures in local applications due to concentration limitations; it reports no new empirical results.

This review discusses the properties and therapeutic potentials of beta-sitosterol, highlighting a need for more detailed studies on its mechanisms and long-term effects in humans; it reports no new results.

In this study, Ganoderma lucidum extract was found to significantly inhibit 5alpha-reductase activity and testosterone-induced prostate growth in rats, suggesting potential use for treating benign prostatic hyperplasia.

This review discusses various herbal therapies, such as Serenoa repens and Pygeum africanum, for treating benign prostatic hyperplasia, noting their potential but highlighting unresolved questions about their efficacy and safety.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This study found that several new pregnane derivatives, especially steroids 16 and 19, demonstrated higher antiandrogenic activity on male hamster models than the commonly used finasteride.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

This study found that octahydrobenzo[c]quinolizin-3-one derivatives, particularly compound 3, were potent and selective inhibitors of the enzyme 5α-reductase type 1.

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

This study found that finasteride was nongenotoxic in Drosophila, while doxazosin mesylate and saw palmetto induced homologous recombination, indicating potential genotoxic actions under the test conditions.

In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.

This review discusses the role of neurosteroids and androgens throughout different life stages, noting the potential disruptions caused by 5α-reductase inhibitors like finasteride, but no new clinical results are reported.

This study reports that structural and biochemical analysis of steroid 5α-reductases clarifies how they mediate steroid reduction with NADPH, potentially aiding in designing targeted therapies.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.